PSMA Therapies

CME

New Advances in Prostate Cancer Care: Emerging Therapies Targeting PSMA

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: September 09, 2022

Expiration: September 08, 2023

Karim Fizazi
Karim Fizazi, MD, PhD

Activity

Progress
1
Course Completed

References

  1. Evans JC, Malhotra M, Cryan JF, et al. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol. 2016;173:3041-3079.
  2. Giraudet AL, Kryza D, Hofman M, et al. PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going? Ther Adv Med Oncol. 2021;13:1-14.
  3. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicenter study. Lancet. 2020;395:1208-1216.
  4. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737-746.
  5. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338-351.
  6. Fizazi K, Tran NP, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352-360.
  7. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13-24.
  8. Armstrong AJ, Szmulewitz R, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974-2986.
  9. Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2x2 factorial design. Lancet. 2022;399:1695-1707.
  10. Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132-1142.
  11. Lutetium Lu 177 vipivotide tetraxetan prescribing information. Millburn, NJ: Novartis; 2022.
  12. Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85-90.
  13. Hofman MS, Violet J, Hicks RJ, et al. 177Lu-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825-833.
  14. Hofman MS, Emmett L, Sandhu S, et al. 177LuLu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797-804.
  15. Sartor O, de Bono J, Chi K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103.
  16. Hofman MS, Emmett L, Sandhu S, et al. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—overall survival after median follow-up of 3 years (ANZUP 1603). Presented at: 2022 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2022. Abstract 5000.
  17. Vaishampayan N, Morris MJ, Krause BJ, et al. 177LuLu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: prior and concomitant treatment subgroup analyses of the VISION trial. Presented at: 2022 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2022. Abstract 5001.
  18. Fizazi K, Herrmann K, Krause BJ, et al. Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract 576MO.
  19. Hotta M, Czernin J, Gafita A, et al. Outcome of patients with PSMA PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis. Presented at: 2022 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2022. Abstract 5042.
  20. Deegen P, Thomas O, Nolan-Stevaux O, et al. The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastate castration-resistant prostate cancer. Clin Cancer Res. 2021;27:2989.
  21. Tran B, Horvath L, Dorff T, et al. Results from a phase 1 study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2020 European Society for Medical Oncology Congress; September 19-21, 2020. Abstract 609O.
  22. De Bono JS, Fong L, Beer T, et al. Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 5013.
  23. Junghans R, Ma Q, Rathore R, et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate. 2016;76:1257-1270.
  24. Narayan V, Gladney W, Plesa G, et al. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. Presented at: 2019 Annual Meeting of the American Society of Clinical Oncology Genitourinary Symposium; January 17-19, 2019. Abstract TPS347.
  25. De Bono JS, Flemin MT, Wang J, et al. MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide. Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology Genitourinary Symposium; February 13-15, 2020. Abstract 99.
  26. Sheehan B, Neeb A, Buroni L, et al. Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer. Clin Canc Res. 2022;28:3104-3115.